Chemical Structure : NCL-1
CAS No.:
1314933-46-4
NCL-1
(NCL1)
Catalog No.: PC-23285Not For Human Use, Lab Use Only.
NCL-1 is a specific small molecule inhibitor of LSD1 (KDM1A) with IC50 of 2.5 uM.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Purity & Documentation Purity:
>98% (HPLC)
Biological Activity
NCL-1 is a specific small molecule inhibitor of LSD1 (KDM1A) with IC50 of 2.5 uM.
NCL-1 promotes inhibitory epigenetic modifications, inhibits cell proliferation of PELP1-driven (MCF-7-PELP1) and HER2-driven (MCF-7-HER2) breast cancer cells with IC50 of 10-16.5 uM.
NCL-1 significantly reduced the proliferation of glioma cells, promotes up regulation of the p53 target genes p21 and PUMA.
NCL-1 mimicks the effects of siRNA-mediated KDM1A knockdown and effectively inhibits KDM1A activity in four neuroblastoma cell lines and a patient-representative cell model.
Physicochemical Properties
|
M.Wt
|
443.55
|
|
Formula
|
C27H29N3O3
|
|
Appearance
|
Solid
|
|
CAS No.
|
|
|
Storage
|
- Solide Powder
-
-20°C 12 Months; 4°C 6 Months
|
- In Solvent
-
-80°C 6 Months; -20°C 6 Months
|
|
Shipping
|
|
|
Solubility
|
10 mM in DMSO
|
|
Chemical Name/SMILES
|
N-((1S)-3-(3-(trans-2-aminocyclopropyl)phenoxy)-1-(benzylcarbamoyl)propyl)benzamide
|
References
1. Valerie Cortez, et al. Breast Cancer Res. 2012 Jul 19;14(4):R108.
2. Ueda R, et al. J Am Chem Soc. 2009;14:17536–17537.
3. Sprüssel A, et al. J Clin Med. 2024 Oct 12;13(20):6081.
Contact Us
sales@probechem.com
